High rate and sustained HBsAg loss achieved with HT-101 plus HT-102 combination therapy in HBeAg-negative, nucleos(t)ide analogue-suppressed patients: ongoing off-treatment results from a multicenter Ib/IIa study

Conference Reports for NATAP

EASL - European Association
for the Study of the Liver
Barcelona, Spain
May 27-30, 2026


High rate and sustained HBsAg loss achieved with HT-101 plus HT-102 combination therapy in HBeAg-negative, nucleos(t)ide analogue-suppressed patients: ongoing off-treatment results from a multicenter Ib/IIa study

	EASL 2026 May 26-30 Barcelona Download the PDF here here Xieer Liang1,